Be-exposed controls (n = 45) | Be-Hypersensitive (n = 22) | |||
---|---|---|---|---|
HLA-DRB1 polymorphisms 1 | N positive subjects (%) | N positive subjects (%) | OR 2 | p 3 |
Ser13 | 28 (62.2%) | 20 (90.9) | 6.07 | 0.015 |
Tyr26 | 7 (15.6%) | 10 (45.5%) | 4.52 | 0.009 |
His32 | 21 (46.7%) | 17 (77.3%) | 3.89 | 0.017 |
Asn37 | 17 (37.8%) | 16 (72.7%) | 4.39 | 0.007 |
Phe47 | 30 (66.7%) | 21 (95.5%) | 10.50 | 0.011 |
Arg74 | 7 (15.6%) | 10 (45.5%) | 4.52 | 0.009 |
HLA-DQB1 polymorphism 4 | ||||
Leu26 | 32 (71.1%) | 21 (95.5%) | 8.53 | 0.021 |
HLA-DRB3 polymorphisms 5 | N = 30 | N = 17 | ||
Arg11 | 8 (26.7%) | 12 (70.6%) | 6.60 | 0.008 |
Tyr26 | 8 (26.7%) | 12 (70.6%) | 6.60 | 0.008 |
Asp28 | 8 (26.7%) | 12 (70.6%) | 6.60 | 0.008 |
Leu38 | 8 (26.7%) | 12 (70.6%) | 6.60 | 0.008 |
Ser60 | 8 (26.7%) | 12 (70.6%) | 6.60 | 0.008 |
Arg74 | 8 (26.7%) | 12 (70.6%) | 6.60 | 0.008 |